← All trials
NCT06086704
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Jan 31, 2027
- Completion date
- Jan 31, 2030
- First posted
- Oct 17, 2023
- Last posted
- Dec 28, 2023
- Enrollment
- 53
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WisconsinLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of WisconsinOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.